In addition to the aforementioned strategies, supplementing γδ T cell therapy with immune checkpoint inhibitors, such as those targeting PD-1/PD-L1 and CTLA4 pathways (65), or novel cancer stem cell-targeting strategies may further bolster the effectiveness and durability of engineered γδ T anti-tumor responses. This evidence concerns the gene CD274 and neoplasm.